
|Videos|June 7, 2022
Patient Selection for Atopic Dermatitis Therapies
Elizabeth A. Swanson, MD, provide insight on identifying the appropriate patients for various therapeutic regimens in atopic dermatitis.
Advertisement
Episodes in this series

Advertisement
Related to this article

Lawrence Eichenfield, MD, discusses phase 2 nemolizumab data in children aged 2 - 11 with atopic dermatitis, from caregiver-rated itch to sleep gains.

Experts outline when to stop cycling topical steroids in chronic hand eczema and where topical delgocitinib now fits.

Dupilumab cut new or worsening allergies by 34% vs placebo in a 12-trial atopic dermatitis meta-analysis, suggesting it may slow the atopic march.
Advertisement
Advertisement
Trending on HCPLive
1
Single Annual Injection Produces Significant and Sustained Lp(a) Reductions
2
Ruvonoflast Reduces hsCRP, Inflammation, CVD Risk With Downstream Effects
3
One COPD Exacerbation Is Too Many: Vickram Tejwani, MD
4
RAPID: Etripamil Converts Two-Thirds of Recurrent PSVT Episodes After Ablation
5






